OmniAb Antibody Discovery Platform
Provider 
Founded 2021
Sells To Enterprise
Pricing Model Recurring
Ownership Private

OmniAb is an antibody-discovery platform built on transgenic OmniRat, OmniMouse, and OmniChicken hosts that produce fully human antibodies.
OmniAb is an antibody-discovery platform operated by OmniAb, Inc., built on transgenic OmniRat, OmniMouse, and OmniChicken hosts whose immunoglobulin loci are engineered to produce fully human antibodies. After immunization, the animals generate diverse, affinity-matured human antibody repertoires that can be mined for therapeutic leads.
The platform is licensed across the biopharmaceutical industry for discovering fully human antibodies against a range of targets. Because the antibodies arise from an in-vivo immune response in humanized animals, the resulting candidates can offer natural diversity and developability for drug development.
Adimab

Adimab Antibody Discovery Platform
adimab.com
AbCellera Biologics

Antibody Discovery Platform
abcellera.com
Prellis Biologics

EXIS
prellisbio.com
| Attribute | OmniAb Antibody Discovery Platform | Adimab Antibody Discovery Platform | Antibody Discovery Platform | EXIS | |
|---|---|---|---|---|---|
| Provider | |||||
| Founded | 2021 | 2007 | 2012 | 2016 | |
| Sells To | Enterprise | Enterprise | Enterprise, Government | Enterprise | |
| Pricing Model | Recurring | Licensing, Recurring | Recurring, Software | Recurring, Software | |
| Ownership | Private | Public | Public | Private equity-backed, Venture-backed |
Provider 
Founded 2021
Sells To Enterprise
Pricing Model Recurring
Ownership Private
Provider 
Founded 2007
Sells To Enterprise
Pricing Model Licensing, Recurring
Ownership Public
Provider 
Founded 2012
Sells To Enterprise, Government
Pricing Model Recurring, Software
Ownership Public
Provider 
Founded 2016
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Private equity-backed, Venture-backed